Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Memantine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 7 Glioblastoma 3 Cognitive Dysfunction 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Tobacco Use Disorder 1 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Neurotoxicity Syndromes 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Motor Activity 1 Melanoma 1 Gliosarcoma 1 Gastrointestinal Neoplasms 1 Fibrosis 1 Epilepsy 1 Ependymoma 1 Craniopharyngioma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Cancer Pain 1 Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

Cyclophosphamide 134 Dexamethasone 113 Rituximab 73 fludarabine 65 Lenalidomide 62 Cytarabine 59 Gemcitabine 55 Bortezomib 51 fludarabine phosphate 49 pembrolizumab 46 venetoclax 45 Etoposide 45 Paclitaxel 44 Carboplatin 44 Cisplatin 43 pomalidomide 41 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 36 Bevacizumab 33 Melphalan 31 Busulfan 31 carfilzomib 30 Calcium Dobesilate 30 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Temozolomide 25 Nivolumab 25 Mycophenolic Acid 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01260467 2015-12-10

Memantine for Recurrent Glioblastoma

University of Rochester

Phase 2 Terminated

4 enrolled 3 charts

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡